A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

An Interventional, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Efficacy of ZP9830 Administered for 8 Weeks in Participants With Plaque Psoriasis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07733089

Enrollment

Registered

2026-07-29

Start date

2026-07-22

Completion date

2027-04-01

Last updated

2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Brief summary

The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.

Interventions

DRUGZP9830

Participants will receive multiple doses of ZP9830. The dose frequency will depend on treatment arm

DRUGPlacebo

Participants will receive multiple doses of placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months). * Participants who have ≥ 2 vulgar psoriatic plaques. * BMI within the range 18.0-35.0 kg/m2 (inclusive). * Further inclusion criteria apply.

Exclusion criteria

* Erythrodermic, predominantly guttate, exclusively palmar/plantar, or generalized pustular psoriasis. * Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate). * Any clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hematology, biochemistry, and urinalysis). * Any clinically significant abnormal findings during the standardized neurological examination conducted at screening. * Use of any concurrent systemic medications that could affect psoriasis or psoriasis evaluation, including corticosteroids, retinoids, cyclosporine, methotrexate, PDE4s (phosphodiesterase 4), or biologic agents within 30 days prior to IMP administration or planned to use during the course of the trial. * Use of concurrent topical medications containing corticosteroids, retinoids, calcitriol or other topical medication relevant to psoriasis treatment (must be discontinued at least 2 weeks prior to baseline). * Use of any biologic or advance systemic therapies for any autoimmune disease within the last 12 months. * Use of UVA, PUVA, or UVB therapy and tanning beds within 4 weeks of baseline or during trial participation. * Further

Design outcomes

Primary

Measure	Time frame	Description
Number of Treatment Emergent Adverse Events (TEAEs)	From baseline (Day 1, predose) to follow-up (Day 85)	To evaluate the safety and tolerability of ZP9830 following administration of multiple doses in participants with plaque psoriasis.

Countries

Netherlands

Contacts

CONTACTClinical Operations

clinicaltrials@zealandpharma.com+45 88 77 36 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026